New drug combo targets tough blood cancers
NCT ID NCT06548230
Summary
This study is testing a new drug, NADUNOLIMAB, in combination with standard treatments for two types of blood cancer: Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). The main goals are to find a safe dose and see if this new combination can help control the disease in adults whose cancer is high-risk or has come back after previous treatment. Researchers will closely monitor patients for side effects and early signs that the treatment is working.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME (MDS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.